8-K: Fortress Biotech Stockholders Approve Director Slate, KPMG, Executive Compensation, and Officer Exculpation at Annual Meeting

Fortress Biotech, Inc. announced the successful passage of all five proposals at its 2025 Annual Meeting, including the election of seven directors, ratification of KPMG LLP, approval of executive compensation, adoption of a three-year Say-on-Pay frequency, and officer exculpation.

Summary

• Fortress Biotech, Inc. held its 2025 Annual Meeting of stockholders virtually on June 17, 2025.
• Stockholders voted on five proposals, all of which were approved.
• Seven directors were elected to serve until the 2026 annual meeting, with significant majority votes for each, including Lindsay A. Rosenwald, M.D. (9,561,328 votes For), Jimmie Harvey, Jr., M.D. (9,510,319 votes For), Malcolm Hoenlein (9,439,773 votes For), Dov Klein, CPA (9,441,597 votes For), J. Jay Lobell (9,182,951 votes For), Kevin L. Lorenz, J.D. (9,510,472 votes For), and Michael S. Weiss (9,528,675 votes For).
• The appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified with 20,400,173 votes For.
• The advisory vote to approve the compensation of named executive officers passed with 9,388,005 votes For.
• Stockholders voted for a three-year frequency for the advisory vote on executive compensation, with 7,421,176 votes, leading the Board to adopt this frequency until the next required vote in 2031.
• The Second Amended and Restated Certificate of Incorporation, including provisions for officer exculpation, was approved with 7,964,484 votes For.

Sentiment

Score: 7

Explanation: The sentiment is positive as all management-backed proposals passed with significant shareholder support, indicating stability and alignment between the company and its investors on key governance matters. The approval of officer exculpation is also a positive for management and officer retention.

Positives

• All five proposals presented at the 2025 Annual Meeting were approved by stockholders, indicating strong shareholder support for the company's current governance and strategic direction.
• The election of all seven nominated directors demonstrates confidence in the existing board and its leadership.
• The ratification of KPMG LLP as the independent auditor provides continuity and stability in financial oversight.
• The approval of named executive officer compensation suggests shareholder alignment with the company's compensation practices.
• The approval of officer exculpation provides enhanced protection for officers, potentially attracting and retaining high-caliber talent.

Future Outlook

The Board has determined that the Company will hold an advisory Say-on-Pay vote every three years until the next required vote on the frequency of Say-on-Pay votes in 2031, aligning with the majority stockholder preference.

Management Comments

• "In light of the vote on Proposal 4, the Board has determined that the Company will hold a Say-on-Pay vote every three years until the next required vote on the frequency of Say-on-Pay votes in 2031."

Industry Context

The approval of officer exculpation is a growing trend among U.S. corporations, particularly following changes in Delaware law, aimed at protecting officers from certain liabilities and attracting executive talent. The routine approval of directors and auditors is standard practice for annual meetings.

Comparison to Industry Standards

• The election of all nominated directors with strong shareholder support is generally consistent with typical annual meeting outcomes for established companies, indicating stable governance.
• The ratification of a major accounting firm like KPMG LLP is a common practice and aligns with corporate governance best practices for public companies.
• The adoption of a three-year Say-on-Pay frequency is a common choice among public companies, balancing shareholder input with administrative efficiency, though some companies opt for annual votes.
• The approval of officer exculpation, particularly in Delaware-incorporated companies, reflects a recent trend following legislative changes (e.g., Delaware General Corporation Law Section 102(b)(7)) allowing for such provisions, aiming to provide broader protection to officers similar to that afforded to directors. This aligns Fortress Biotech with a growing number of companies seeking to mitigate litigation risks for their executive teams.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the election of directors, the ratification of the auditor, the approval of executive compensation, the frequency of Say-on-Pay votes, and the officer exculpation provision, which affects their rights and potential recourse.
• Management/Officers: Benefit from the approval of their compensation and the new officer exculpation provision, which offers increased legal protection.
• Employees: Indirectly impacted by the stability of management and governance, which can influence company strategy and long-term prospects.

Next Steps

• The elected directors will hold office until the 2026 annual meeting of stockholders.
• The Company will hold a Say-on-Pay vote every three years until the next required vote on the frequency of Say-on-Pay votes in 2031.

Key Dates

Keywords

Fortress Biotech, FBIO, SEC filing, 8-K, annual meeting, stockholder vote, corporate governance, director election, KPMG, executive compensation, Say-on-Pay, officer exculpation, proxy statement